The inverse association of MPO with thrombotic events and the alignment of cfDNA with thrombosis but not the ThroLy score suggests that NET biomarkers may act as independent drivers of thrombosis, consistent with previous reports showing elevated NET markers in cancer-associated thrombosis and their potential as predictive biomarkers [26,27]. The gene discussed is MPO; the disease is cancer.